Treatment of Nasal Staphylococcus Aureus Colonization in Patients With HHT
Märksõnad
Abstraktne
Kirjeldus
Hereditary hemorrhagic telangiectasia is a vascular dysplasia characterized by the development of mucocutaneous telangiectasia and arteriovenous malformations in organs such as brain, lung, liver and tube digestivo. Is considered a rare disease, although It means that there is a substantial underdiagnosis. The overall prevalence is 1/5000.
Approximately 60% of the general population hosts strains of Staphylococcus aureus (S. aureus) intermittently and are called intermittent carriers, 20% represent persistent carriers harboring the same strain of S. aureus and 20% of the population are never carriers.
On this concept, one might think that HHT patients in whom there is an active and pathological vascular remodeling that causes bleeding, and inflammation is a known activator of abnormal angiogenesis; reducing an inflammatory factor as microbial through the eradication of nasal S. aureus could be useful to reduce bleeding in this population, directly impacting on quality of life.
Kuupäevad
| Viimati kinnitatud: | 10/31/2016 |
| Esmalt esitatud: | 08/08/2016 |
| Hinnanguline registreerumine on esitatud: | 11/08/2016 |
| Esmalt postitatud: | 11/14/2016 |
| Viimane värskendus on esitatud: | 11/08/2016 |
| Viimati värskendus postitatud: | 11/14/2016 |
| Õppe tegelik alguskuupäev: | 05/31/2017 |
| Eeldatav esmane lõpetamise kuupäev: | 05/31/2017 |
| Eeldatav uuringu lõpetamise kuupäev: | 11/30/2017 |
Seisund või haigus
Sekkumine / ravi
Drug: Mupirocina
Other: Control
Faas
Käerühmad
| Arm | Sekkumine / ravi |
|---|---|
| Experimental: Mupirocina topical mupirocin nasal ointment and nasal solid petroleum jelly for 5 consecutive days and then just nasal solid petroleum jelly to complete the 60 total days | Drug: Mupirocina Mupirocin ointment in the nose for 5 days |
| Placebo Comparator: Control topical placebo nasal ointment and nasal solid petroleum jelly for 5 consecutive days and then just nasal solid petroleum jelly to complete the 60 total days | Other: Control Placebo ointment in the nose for 5 days |
Abikõlblikkuse kriteeriumid
| Õppimiseks sobivad vanused | 18 Years To 18 Years |
| Uuringuks kõlblikud sood | All |
| Võtab vastu tervislikke vabatahtlikke | Jah |
| Kriteeriumid | Inclusion Criteria: - Patients over 18 years with possible or confirmed HHT as diagnostic criteria Curaçao. - Patients with nasal S. aureus colonization culture positive Exclusion Criteria: - Refusal to participate in the study or the informed consent process. - Hypersensitivity or contraindication for topical mupirocin. |
Tulemus
Esmased tulemusnäitajad
1. Nosebleed by sadick scale [60 days]
Sekundaarsed tulemusmõõdud
1. Prevalence of nasal colonization with Staphylococcus in patients with HHT by nasal cultive [60 days]
